Among 10,462 UK Biobank participants who later developed cancer, higher cardiorespiratory fitness (CRF) at baseline was associated with dramatically lower all-cause mortality after diagnosis. Relative to a median VO2max of 27.9 ml·kg⁻¹·min⁻¹, those at 12.5 ml·kg⁻¹·min⁻¹ faced 59% higher mortality (HR 1.59; 95% CI 1.28–1.98), while those at 44.5 ml·kg⁻¹·min⁻¹ had 29% lower risk. Fifteen-year survival spanned 39.3% to 77.4% across the CRF range — a 38-percentage-point gap. Handgrip strength also predicted survival (37% higher mortality at 12 kg vs. median), but its benefit plateaued at ~32 kg with no further gain, and the survival range was narrower at 22 points.
This is a meaningfully confirmatory finding that strengthens the case for aerobic fitness as a modifiable pre-cancer survival asset. Unlike handgrip strength — which likely proxies lean mass and general vitality — CRF showed a continuously declining risk curve with no plateau, suggesting that even mid-to-high aerobic fitness gains deliver incremental survival benefit. The physiological logic is coherent: higher VO2max supports treatment tolerance, immune surveillance, and reduced metabolic inflammation. Crucially, this is pre-diagnostic fitness — meaning these protective effects were established before cancer appeared, reinforcing lifelong aerobic exercise as a genuine longevity investment. Limitations include estimated (not directly measured) VO2max and observational design, which cannot confirm causality. Heterogeneity across cancer types also remains unaddressed. Still, the dose-response magnitude here is clinically striking.